5型磷酸二酯酶抑制剂在下尿路症状和勃起功能障碍中的作用机制：一氧化氮-环磷酸鸟苷途径。 - Suppr

Mechanism of action of PDE5 inhibitors in LUTS and ED: the NO-cGMP pathway.

作者信息

Giuliano François

出版信息

Eur Urol. 2009 Jan;55(1):49-51. doi: 10.1016/j.eururo.2008.10.007. Epub 2008 Oct 14.

DOI:10.1016/j.eururo.2008.10.007

PMID:18938025

Abstract

摘要

相似文献

Mechanism of action of PDE5 inhibitors in LUTS and ED: the NO-cGMP pathway.

Eur Urol. 2009 Jan;55(1):49-51. doi: 10.1016/j.eururo.2008.10.007. Epub 2008 Oct 14.

The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors.

Eur Urol. 2009 Jan;55(1):38-48. doi: 10.1016/j.eururo.2008.08.062. Epub 2008 Sep 4.

PDE5 inhibitors for LUTS.

Prostate Cancer Prostatic Dis. 2009;12(4):316-24. doi: 10.1038/pcan.2009.27. Epub 2009 Aug 18.

Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?

BJU Int. 2009 Aug;104(4):511-7. doi: 10.1111/j.1464-410X.2009.08418.x. Epub 2009 Feb 23.

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Eur Urol. 2016 Jul;70(1):124-133. doi: 10.1016/j.eururo.2015.12.048. Epub 2016 Jan 22.

Editorial comment.

Urology. 2010 Jun;75(6):1458. doi: 10.1016/j.urology.2009.10.071.

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.

Expert Opin Pharmacother. 2010 May;11(7):1109-22. doi: 10.1517/14656561003698131.

A placebo-controlled exploratory study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with storage lower urinary tract symptoms associated with a clinical diagnosis of overactive bladder.

BJU Int. 2010 Sep;106(5):666-73. doi: 10.1111/j.1464-410X.2010.09205.x.

Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

BJU Int. 2011 Jun;107(12):1943-7. doi: 10.1111/j.1464-410X.2010.09759.x. Epub 2010 Nov 5.

Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction.

Urology. 2010 Jun;75(6):1452-8. doi: 10.1016/j.urology.2009.09.093. Epub 2010 Feb 16.

引用本文的文献

Low-Intensity Pulsed Ultrasound Enhanced Adipose-Derived Stem Cell-Mediated Angiogenesis in the Treatment of Diabetic Erectile Dysfunction through the Piezo-ERK-VEGF Axis.

Stem Cells Int. 2022 Jul 29;2022:6202842. doi: 10.1155/2022/6202842. eCollection 2022.

The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase-5 inhibitors.

Cent European J Urol. 2014;67(3):314-8. doi: 10.5173/ceju.2014.03.art20. Epub 2014 Aug 18.

Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS.

Nat Rev Urol. 2014 Apr;11(4):231-41. doi: 10.1038/nrurol.2014.53. Epub 2014 Mar 11.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Mechanism of action of PDE5 inhibitors in LUTS and ED: the NO-cGMP pathway.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献